Recently, the U.S. patent application "Acylated glp-1 derivative" — a global counterpart patent application filed and owned by Sciwind Biotherapeutics, with the theme "Acylated GLP-1 Derivatives" — has been granted. Previously, five invention patents in this same family had been granted in Japan, South Korea, Australia, and Russia, including two in Australia.

Beijing Caihe Law Firm was entrusted by Sciwind Biotherapeutics to fully represent the international phase legal affairs of the PCT application for this series of counterpart patent applications, and provided full-cycle consulting services for the overseas national phase of this series of counterpart patent applications, including selecting foreign firms, preparing documents, and responding to office actions. Sciwind Biotherapeutics is a science-driven, international, clinical-stage biopharmaceutical company focusing on the development of biomacromolecular new drugs in the field of metabolic diseases. It is committed to developing innovative drugs with independent intellectual property rights and realizing the global industrialization and commercialization of products. Headquartered in Hangzhou, the company has its R&D and domestic registration center in Beijing, and has successively established wholly-owned subsidiaries in Australia and the United States, which are respectively responsible for overseas clinical development, overseas registration applications and BD business. In addition, it also has an office in Shanghai. Based on several core platforms, Sciwind Biotherapeutics has established a number of innovative drug R&D pipelines in different R&D stages. The company has now obtained 4 clinical trial approvals, 2 of which have been rapidly advanced to Phase 2 clinical trials, and overseas clinical development has been laid out in advance. Sciwind Biotherapeutics' entrepreneurial team, R&D pipeline and development capabilities have been recognized by many investment institutions, and it has received strategic investments from institutions such as IDG Capital, Zhengxingu Capital, LYFE Capital, Junlian Capital, Shiyu Capital, and Haibang Investment, providing effective financial guarantee for the company's long-term development.